CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2014 San Antonio Breast Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer
Dr. Gradishar Discusses the Results of the BOLERO-1 Trial
Dr. Chlebowski on How Weight Loss Improves TNBC Survival
Oncology Conference Articles
Gene Test Predicts DCIS Recurrence Risk
A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk
Women With Triple-Negative Breast Cancer May Reap Greater Survival Benefit From Nutrition Intervention
Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptorâ€“negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.
HR-Negative Subgroup Data Offer Silver Lining to Everolimus Frontline Failure in BOLERO-1
Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer
Upfront Fulvestrant Improves Survival Over Anastrozole in HR-Positive MBC
Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer
Chemo Adds No Benefit to Bisphosphonate In Older Breast Cancer Patients
Older patients with moderate- or high-risk breast cancer had a similar disease-free survival with the bisphosphonate therapy ibandronate alone or in combination with capecitabine.
Tamoxifen's Sustained Power to Prevent Breast Cancer in High-Risk Women Confirmed
Five years of tamoxifen continues to offer protection against breast cancer, reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.
Ovarian Suppression Emerges as "Practice-Changing" Option for Younger, Premenopausal Breast Cancer Patients
Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent-tamoxifen, compared with standard tamoxifen alone, according to results from the phase III SOFT trial.
TNBC Subtype Responds Favorably to Neoadjuvant Bevacizumab
The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.
Nab-Paclitaxel Wins Neoadjuvant Taxane Battle in Breast Cancer Trial
Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.
Pembrolizumab Elicits Antitumor Responses in TNBC
The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.
Early Data Find the PI3K Inhibitor Pictilisib Benefits a Subset of Patients With MBC
The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.
Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels
Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.
FDA Approval in HCC, Breakthrough Designation in MCL, and More
Treatment Goals in Refractory mCRC
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer
FDA Approves Third Trastuzumab Biosimilar
Olaratumab Falls Short in Phase III Soft Tissue Sarcoma Trial
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.